MGNX – Macrogenics Inc
MacroGenics, Inc.MGNX
$1.29Name : MacroGenics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $81,386,488.00
EPSttm : -1.07
MacroGenics, Inc.
$1.29
3.20%$0.04Float Short %
9.69
Margin Of Safety %
Put/Call OI Ratio
1.22
EPS Next Q Diff
-0.46
EPS Last/This Y
-1.82
EPS This/Next Y
2.89
Price
1.28
Target Price
5.8
Analyst Recom
2.38
Performance Q
-59.43
Relative Volume
0.67
Beta
2.18
Ticker: MGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-12 | MGNX | 2.38 | 1.72 | 0.00 | 3964 |
| 2025-03-13 | MGNX | 2.19 | 1.71 | 0.00 | 3971 |
| 2025-03-14 | MGNX | 2.22 | 1.70 | 0.00 | 3981 |
| 2025-03-17 | MGNX | 2.18 | 1.70 | 0.00 | 3981 |
| 2025-03-18 | MGNX | 2.05 | 1.69 | 6.00 | 3983 |
| 2025-03-19 | MGNX | 2.2 | 1.70 | 0.51 | 3996 |
| 2025-03-20 | MGNX | 2.12 | 1.66 | 1.90 | 4074 |
| 2025-03-21 | MGNX | 1.99 | 1.66 | 0.59 | 4103 |
| 2025-03-24 | MGNX | 1.96 | 1.61 | 8.67 | 4047 |
| 2025-03-25 | MGNX | 1.8 | 1.61 | 0.14 | 4051 |
| 2025-03-26 | MGNX | 1.565 | 1.58 | 8.93 | 4059 |
| 2025-03-27 | MGNX | 1.48 | 1.74 | 2.53 | 4435 |
| 2025-03-28 | MGNX | 1.26 | 1.90 | 4.62 | 4686 |
| 2025-03-31 | MGNX | 1.27 | 1.25 | 25.00 | 3681 |
| 2025-04-01 | MGNX | 1.22 | 1.26 | 0.08 | 3708 |
| 2025-04-02 | MGNX | 1.225 | 1.25 | 2.00 | 3710 |
| 2025-04-03 | MGNX | 1.155 | 1.25 | 6.18 | 3710 |
| 2025-04-04 | MGNX | 1.07 | 1.34 | 142.00 | 3844 |
| 2025-04-07 | MGNX | 1.105 | 1.24 | 74.50 | 3694 |
| 2025-04-08 | MGNX | 1.12 | 1.24 | 74.50 | 3694 |
| 2025-04-09 | MGNX | 1.3 | 1.18 | 4.50 | 3587 |
| 2025-04-10 | MGNX | 1.25 | 1.17 | 999.99 | 3589 |
| 2025-04-11 | MGNX | 1.285 | 1.22 | 999.99 | 3664 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-12 | MGNX | 2.38 | 21.3 | - | -1.38 |
| 2025-03-13 | MGNX | 2.20 | 21.3 | - | -1.38 |
| 2025-03-14 | MGNX | 2.22 | 21.3 | - | -1.38 |
| 2025-03-17 | MGNX | 2.18 | 21.3 | - | -1.38 |
| 2025-03-18 | MGNX | 2.05 | 21.3 | - | -1.38 |
| 2025-03-19 | MGNX | 2.18 | 21.3 | - | -1.38 |
| 2025-03-20 | MGNX | 2.10 | 21.3 | - | -1.38 |
| 2025-03-21 | MGNX | 1.99 | 21.3 | - | -1.38 |
| 2025-03-24 | MGNX | 1.96 | - | - | -1.38 |
| 2025-03-25 | MGNX | 1.79 | - | - | -1.38 |
| 2025-03-26 | MGNX | 1.56 | - | - | -1.38 |
| 2025-03-27 | MGNX | 1.49 | - | - | -1.38 |
| 2025-03-28 | MGNX | 1.26 | 17.9 | - | -2.89 |
| 2025-03-31 | MGNX | 1.27 | 17.9 | - | -2.89 |
| 2025-04-01 | MGNX | 1.22 | 17.9 | - | -2.89 |
| 2025-04-02 | MGNX | 1.22 | 17.9 | - | -2.89 |
| 2025-04-03 | MGNX | 1.15 | 17.9 | - | -2.89 |
| 2025-04-04 | MGNX | 1.07 | 17.9 | - | -2.89 |
| 2025-04-07 | MGNX | 1.11 | 17.9 | - | -2.89 |
| 2025-04-08 | MGNX | 1.10 | 17.9 | - | -2.89 |
| 2025-04-09 | MGNX | 1.30 | 17.9 | - | -2.89 |
| 2025-04-10 | MGNX | 1.26 | 17.9 | - | -2.89 |
| 2025-04-11 | MGNX | 1.28 | 17.9 | - | -2.89 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-12 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-13 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-14 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-17 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-18 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-19 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-20 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-21 | MGNX | -0.01 | -4.92 | 8.85 |
| 2025-03-24 | MGNX | -0.01 | -4.90 | 8.85 |
| 2025-03-25 | MGNX | -0.01 | -4.90 | 8.85 |
| 2025-03-26 | MGNX | -0.01 | -4.90 | 8.57 |
| 2025-03-27 | MGNX | -0.01 | -4.90 | 8.57 |
| 2025-03-28 | MGNX | -0.01 | -4.90 | 8.57 |
| 2025-03-31 | MGNX | -0.01 | -4.93 | 8.57 |
| 2025-04-01 | MGNX | -0.01 | -4.93 | 8.57 |
| 2025-04-02 | MGNX | -0.01 | -4.93 | 8.57 |
| 2025-04-03 | MGNX | -0.01 | -4.93 | 8.57 |
| 2025-04-04 | MGNX | -0.01 | -4.93 | 8.57 |
| 2025-04-07 | MGNX | -0.01 | -4.98 | 8.57 |
| 2025-04-08 | MGNX | -0.01 | -4.98 | 8.57 |
| 2025-04-09 | MGNX | -0.01 | -4.98 | 8.57 |
| 2025-04-10 | MGNX | -0.01 | -4.98 | 9.69 |
| 2025-04-11 | MGNX | -0.01 | -4.98 | 9.69 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.25
Avg. EPS Est. Current Quarter
-0.69
Avg. EPS Est. Next Quarter
-0.71
Insider Transactions
-0.01
Institutional Transactions
-4.98
Beta
2.18
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
43
Growth Score
51
Sentiment Score
71
Actual DrawDown %
96.5
Max Drawdown 5-Year %
-97
Target Price
5.8
P/E
Forward P/E
PEG
P/S
0.54
P/B
0.7
P/Free Cash Flow
EPS
-1.07
Average EPS Est. Cur. Y
-2.89
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-44.66
Relative Volume
0.67
Return on Equity vs Sector %
-77.3
Return on Equity vs Industry %
-64.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.12
EBIT Estimation
MacroGenics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 341
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading